logo
Share SHARE
FONT-SIZE Plus   Neg

Wyndham Worldwide Q1 Profit Falls But Adjusted Earnings Tops Street

Hospitality services and products provider Wyndham Worldwide Corporation (WYN) Wednesday posted lower profit for the first quarter reflecting increased expenses. However, adjusted earnings surpassed the Street estimates.

For the three-month period, the company posted net income attributable to shareholders of $27 million versus prior-year earnings of $32 million. On a per share basis, earnings for the period fell to $0.19 from $0.21 last year.

On an adjusted basis, the firm posted earnings of $0.71 for the period. Nine analysts on average polled by Thomson Reuters estimated earnings per share of $0.67 for the quarter. Analysts estimates typically exclude one-time items.

Net revenue for the quarter climbed to $1.133 billion from $1.036 billion a year earlier and was in line with consensus estimate of $1.13 billion.

Early extinguishment of debt cost the company $111 million this year as opposed to $ 106 million last year.

Looking forward, the company sees adjusted earnings per share of approximately $3.60 to $3.70 and revenue of approximately $4.925 to $5.100 billion for the full fiscal year. Analysts are currently looking for earnings of $3.67 on revenue of $4.95 billion.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Carnival Corporation & plc (CCL, CCL.L, CUK) reported a profit for the third-quarter that increased 17 percent from the prior year. The company said it is well on track to deliver nearly 25 percent earnings growth in 2016. It raised adjusted earnings per share guidance for 2016. Samsung Electronics Co., Ltd. said it will delay restarting the sale of its Galaxy Note 7 phone in South Korea. The decision is said to reflect the requirement of more time for the global recall as dozens of devices caught fire. Shares of Marinus Pharmaceuticals Inc. (MRNS) have gained over 35% in the last seven trading days in the run-up to the exploratory phase II study results of Ganaxolone, scheduled for this month.
comments powered by Disqus
Follow RTT